Accumulating evidence points to an important role of the MCP-1/CCR2 pathway in the development of obesity-associated inflammation in WAT [6, 8, 9, 12, 13] and subsequent development of NASH [9, 10, 14]. Here, CCR2 is linked to metabolic dysfunction-associated steatohepatitis.